



## PHARMACEUTICAL 2019










## PHARMACEUTICAL 2019





The relative strengths and weaknesses of Xenetic Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xenetic Biosciences Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 221% points. The greatest weakness of Xenetic Biosciences Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 66% points.

The company's Economic Capital Ratio, given in the ranking table, is 103%, being 66% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	1,194
Cost of Goods Sold	0
Intangible Assets	3,283
Liabilities, Current	1,600
Liabilities, Non-Current	0
Other Assets	9,949
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	2,919
Other Net Income	-24
Other Revenues	0
Property and Equipment	5.0
Research and Development	2,884
Selling, General and Administrative Expense	4,392

Output Variable	Value in 1000 USD
Assets	14,431
Liabilities	4,518
Expenses	7,276
Revenues	0
Stockholders Equity	9,913
Net Income	-7,300
Comprehensive Net Income	-7,300
Economic Capital Ratio	103%

